The SONIA study evaluated the efficacy of CDK4/6i added to either first- or second-line endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2neu) receptor-negative breast cancer. Here, CDK4 is linked to breast carcinoma.